Therefore, there are still many questions to be answered, such as what are the upstream regulators of TRA16 and its interaction sites with ERβ and TR2, and whether the TRA16 expression can be detected in circulating cancer cells in patient blood that could be used to easily screen and diagnose patients with NSCLC, all of which will be investigated in future studies. The gene discussed is NR2C2AP; the disease is non-small cell lung carcinoma.